Mizuno M, Yoshida J
Department of Molecular Neurosurgery, Nagoya University, Graduate School of Medicine.
Nihon Rinsho. 2001 Jan;59(1):76-80.
Recent development of therapeutic modalities in neurosurgery has brought about dramatic improvement for prognosis of brain tumors. Nevertheless, malignant glioma is one of the most formidable neoplasms in humans. According to a report by the Committee of Brain Tumor Registry of Japan, five-year relative survival rate of malignant gliomas is less than 10%. Malignant gliomas grow aggressively infiltrating into the surrounding normal brain tissue. So that total surgical resection is impossible. The tumors respond to radiation and chemotherapy, however, the efficiency has sustained transiently. The advert of new strategies for the treatment of malignant gliomas has long been awaited. We have developed a cytokine gene therapy for malignant glioma since about 10 years ago. Here, we introduce both suicide gene therapies and immune gene therapies including our case(IFN-beta gene therapy).
神经外科治疗方式的最新进展已使脑肿瘤的预后得到显著改善。然而,恶性胶质瘤是人类最棘手的肿瘤之一。根据日本脑肿瘤登记委员会的一份报告,恶性胶质瘤的五年相对生存率低于10%。恶性胶质瘤生长迅速,浸润周围正常脑组织。因此,无法进行完全手术切除。肿瘤对放疗和化疗有反应,然而,疗效只是暂时维持。长期以来,人们一直期待着治疗恶性胶质瘤的新策略。大约10年前,我们就已开展针对恶性胶质瘤的细胞因子基因治疗。在此,我们介绍自杀基因治疗和免疫基因治疗,包括我们的病例(干扰素-β基因治疗)。